Composition containing lactic acid bacteria fermented product

Abstract

To provide novel effects and uses of lactic acid bacteria-fermented products.SOLUTION: The present invention provides an oral composition for improving or keeping the gum which contains lactic acid bacteria-fermented broccoli.SELECTED DRAWING: None

Description

Technical Field

[0001] The present disclosure relates to a composition containing a lactic acid bacterium fermented product and its uses, etc. The content of all documents described in this specification is incorporated herein by reference.

Background Art

[0002] It has been studied that various effects are exerted by lactic acid bacterium fermented products. For example, it is known that effects such as improvement of the intestinal barrier (Patent Document 1) or improvement of the skin (Patent Document 2) are exerted.

Prior Art Documents

Patent Documents

[0003]

Patent Document 1

Patent Document 2

Summary of the Invention

Problems to be Solved by the Invention

[0004] The present inventors explored novel effects and uses of lactic acid bacterium fermented products.

Means for Solving the Problems

[0005] The present inventors found that oral ingestion of broccoli fermented by lactic acid bacteria (lactic acid bacterium fermented broccoli), among lactic acid bacterium fermented products, can improve or maintain the gingiva, and further made improvements.

[0006] The present disclosure includes, for example, the subject matters described in the following items. Item 1. An oral composition for improving or maintaining the gingiva, containing lactic acid bacterium fermented broccoli. Item 2. An oral composition containing lactic acid bacteria-fermented broccoli for suppressing the expression of inflammatory cytokines in the gums. Section 3. An oral composition according to item 1 or 2, which is a food composition. [Effects of the Invention]

[0007] An oral composition for improving or maintaining gums is provided, which contains lactic acid bacteria-fermented broccoli. [Brief explanation of the drawing]

[0008] [Figure 1a] The results of measuring TNF-α gene expression in periodontal tissue of mice orally fed a normal diet, a high-fat diet, or a high-fat diet and lactic acid bacteria-fermented broccoli are shown. [Figure 1b] The results of measuring IL-1β gene expression in periodontal tissue of mice orally fed a normal diet, a high-fat diet, or a high-fat diet and lactic acid bacteria-fermented broccoli are shown. [Figure 1c] The results of PAI-1 gene expression measurements in periodontal tissue of mice orally fed a normal diet, a high-fat diet, or a high-fat diet and lactic acid bacteria-fermented broccoli are shown. [Modes for carrying out the invention]

[0009] The embodiments included in this disclosure will be described in more detail below. This disclosure preferably includes, but is not limited to, lactic acid fermented broccoli-containing compositions and their uses, and encompasses everything disclosed herein and recognizable to those skilled in the art.

[0010] The composition included in this disclosure is an oral composition containing lactic acid bacteria-fermented broccoli. Hereinafter, the composition included in this disclosure may be referred to as "the composition of this disclosure." The composition of this disclosure may have a gingival improvement or maintenance effect. For this reason, it is preferably used for gingival improvement or maintenance.

[0011] As described above, lactic acid fermented broccoli is obtained by fermenting broccoli with lactic acid bacteria.

[0012] The lactic acid bacteria used are not particularly limited as long as they produce lactic acid bacteria-fermented broccoli that exhibits the above effects, and any known orally ingestible lactic acid bacteria can be used. For example, lactic acid bacteria of the genera Lactobacillus and Lactococcus can be used, and more specifically, Lactobacillus pentosus, Lactobacillus bulgaricus, Lactobacillus gasseri, Lactobacillus acidophilus, Lactococcus lactis, Lactococcus cremoris, etc. Among these, Lactobacillus pentosus is preferred. Lactic acid bacteria can be used individually or in combination of two or more types.

[0013] Furthermore, there are no particular restrictions on fermentation conditions. For example, if you crush and heat broccoli, then strain the broccoli puree, add 1 x 10 9 Broccoli can be fermented by inoculating it with a few lactic acid bacteria and letting it stand at 30°C for about 20 hours. It is preferable to inoculate the broccoli puree with lactic acid bacteria by adding a lactic acid bacteria solution at a concentration of approximately 4-5% by mass of the broccoli puree.

[0014] The content of lactic acid fermented broccoli in the composition of this disclosure is not particularly limited, but is preferably about 0.1 to 100% by mass, more preferably about 1 to 99% by mass, 2 to 90% by mass, or 5 to 50% by mass.

[0015] The amount of fermented broccoli to be ingested is not particularly limited. Also, the shape of the fermented broccoli is not particularly limited. For example, the fermented broccoli may be a dried product (preferably a dried powder, more preferably a lyophilized powder), or alternatively, for example, a fermented broccoli puree. In terms of the dried product equivalent, it is preferable that the fermented broccoli is ingested at about 100 to 1000 mg per day (particularly per day for an adult). Regarding the amount of lactic acid bacteria-fermented broccoli contained in the composition of the present disclosure, it can also be set by referring to the daily intake amount of lactic acid bacteria-fermented broccoli. The amount of lactic acid bacteria-fermented broccoli contained in the composition can be, for example, 1 / 2 or 1 / 3 of the daily intake amount of lactic acid bacteria-fermented broccoli, and the composition can be ingested several times a day (2 or 3 times).

[0016] When using the composition of the present disclosure for improving or maintaining the gingiva, not only the subjects for whom gingival improvement is desired, but also the subjects with no major abnormalities in the gingiva can be prophylactically used for maintaining the gingiva. Preferred subjects for whom gingival improvement is desired include subjects with inflamed gingiva, subjects with receded gingiva, etc., and more specifically, for example, subjects with gingivitis and / or periodontitis. Also, periodontal disease patients are preferably included as such subjects.

[0017] Although not wishing to be bound by theory, by orally ingesting the composition of the present disclosure, the expression of specific cytokines (particularly inflammatory cytokines) in the gingiva can be suppressed, thereby achieving an effect of improving or maintaining the gingiva. More specifically, examples of the cytokines include TNF-α (tumor necrosis factor-α), IL-1β (Interleukin-1β), and PAI-1 (plasminogen activator inhibitor-1).

[0018] For example, if the above-mentioned cytokines are overproduced, they activate gingival fibroblasts and osteoclasts. The activated gingival fibroblasts produce collagenase and destroy the gingival tissue. In addition, the activated osteoclasts promote alveolar bone resorption, which also causes gingival recession (gum recession), making it impossible to maintain healthy gums. Therefore, it can be said that suppressing the expression of cytokines is important. Incidentally, PAI-I is a type of cytokine produced by mast cells and is known to be involved in the progression of thrombosis. There are also reports of a correlation between the amount of PAI-1 in the blood and the periodontal condition, and it is considered possible that the progression of periodontal disease is promoted by a decrease in blood flow to the periodontal tissue. Therefore, it can be said that suppressing the expression of PAI-1 is important.

[0019] In addition, from the above, the composition of the present disclosure can also be preferably used to suppress the expression of cytokines.

[0020] The composition of the present disclosure may contain components other than lactic acid bacteria-fermented broccoli as long as the effects are not impaired. For example, it may contain pharmacologically or food hygienically acceptable bases, carriers, additives, etc. Also, the form of the composition of the present invention is not particularly limited, and for example, it may be an oral pharmaceutical composition or a food composition. In the case of a food composition, it may be, for example, processed food, beverages, health foods (nutritional functional foods, foods for specified health use, etc.), supplements, foods for patients (hospital meals, patient meals or care foods, etc.).

[0021] In this specification, "comprising" includes "consisting essentially of" and "consisting of". Also, the present disclosure includes all arbitrary combinations of the constituent elements described in this specification.

[0022] Furthermore, the various characteristics (properties, structure, function, etc.) described in each embodiment of this disclosure above may be combined in any way to identify the subject matter covered by this disclosure. In other words, this disclosure covers all subject matter consisting of any combination of the combinable characteristics described herein. [Examples]

[0023] The embodiments of this disclosure will be described in more detail below with examples, but the embodiments of this disclosure are not limited to the examples below.

[0024] Animals used Three-week-old male mice (C57BL / 6J (SPF)) were purchased from Charles River Japan Co., Ltd. and used in the experiment. The acclimatization period was from arrival to the day of group division. The quarantine period was set to 7 days, with the arrival day being day 0. During the quarantine and acclimatization period and the test period for group A, D12450J (normal feed (feed 1), RESEARCH DIETS, INC., lot number: 20080303) was placed on the cage lid, and during the test periods for groups B and C, D12492 (high-fat diet (HFD; feed 2), RESEARCH DIETS, INC., lot numbers: 20090202, 20110303) was placed, and the mice were allowed to feed freely except during fasting periods. Drinking water was freely provided throughout the test period using a polysulfone water dispenser (stainless steel tip).

[0025] Grouping Based on body weight measured on the last day of the quarantine and acclimatization period, the animals were divided into groups using a stratified continuous randomization method according to the table below.

[0026] [Table 1]

[0027] The test substance used was broccoli fermented with Lactobacillus pentosus. The fermentation was carried out as follows: After crushing and heating the broccoli, 1 x 10⁻¹⁶ of the broccoli puree was added. 9Approximately 100 lactic acid bacteria were inoculated and allowed to stand at 30°C for about 20 hours to ferment. Inoculation of lactic acid bacteria into the broccoli puree was performed by adding a lactic acid bacteria solution at a concentration of 4% by mass of the broccoli puree's weight.

[0028] Furthermore, the fermented broccoli obtained was freeze-dried and used as a test substance in powder form.

[0029] Distilled water containing the test substance was administered to mice via a tube. Mice in the control group (not administered the test substance) were administered distilled water via a tube. The administration period was 77 days. After the administration period, the mice were fasted overnight, anesthetized, and dissected. Periodontal tissue (left and right sides of the maxilla, and right side of the mandible) was collected. For the gingival tissue, the mice were cut in a frozen state with a scalpel, and total RNA was collected using the Total RNA Mini Kit (Bio-Rad). cDNA was then created by reverse transcription. The changes in the expression of the following genes were then observed by real-time PCR. The results are shown in Figures 1a-1c, as relative values ​​with the gene expression level in the group fed a normal diet (Group A: control) set to 1. ·TNF-α (tumor necrosis factor-α) • IL-1β (Interleukin-1β) • PAI-1 (plasminogen activator inhibitor-1)

[0030] In each figure, + indicates <0.1, * indicates p < 0.05, and ** indicates p < 0.01. Also, FB indicates lactic acid fermented broccoli.

Claims

1. An oral composition for improving or maintaining gums, containing lactic acid fermented broccoli, This is a composition for suppressing the expression of PAI-1. A composition wherein the lactic acid bacterium is Lactobacillus pentosa.

2. An oral composition containing lactic acid bacteria-fermented broccoli for suppressing the expression of inflammatory cytokines in the gums, The aforementioned inflammatory cytokine is PAI-1, A composition wherein the lactic acid bacterium is Lactobacillus pentosa.

3. An oral composition according to claim 1 or 2, which is a food composition.

Images